Key result
Enoxaparin use for VTE prophylaxis following total hip or knee arthroplasty was associated with a lower rate of any postoperative bleeding compared with rivaroxaban (2.2% vs 6.8%, P=0.004).
Why the study?
Does enoxaparin reduce postoperative bleeding compared to rivaroxaban in patients undergoing total hip or knee arthroplasty?
Population
Patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA)
Comparison
Enoxaparin for prevention of venous… vs Rivaroxaban for prevention of venous…
Design
Cohort
Follow-up
postoperative
Authors
Loading...
May warrant caution with rivaroxaban for VTE prophylaxis post-arthroplasty; leaves open whether bleeding differences persist in prospective trials.
Cohort
Does enoxaparin reduce postoperative bleeding compared to rivaroxaban in patients undergoing total hip or knee arthroplasty?
Absolute Event Rate: 2.2% vs 6.8%
p-value: p=0.004
In patients undergoing total hip or knee arthroplasty, enoxaparin for VTE prophylaxis was associated with significantly lower rates of postoperative bleeding compared to rivaroxaban.
Ricket et al. (2016) conducted a cohort in Venous thromboembolism prophylaxis following total hip or knee arthroplasty. Enoxaparin vs. Rivaroxaban was evaluated on Any postoperative bleeding (composite of major and clinically relevant nonmajor bleeding) (p=0.004). Enoxaparin use for VTE prophylaxis following total hip or knee arthroplasty was associated with a lower rate of any postoperative bleeding compared with rivaroxaban (2.2% vs 6.8%, P=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: